Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17527386 | 0.88 | SCN9A (0.36) | KCNH2SCN5ASCN9A | |
| SCHEMBL17527388 | 0.88 | SCN9A (0.36) | KCNH2SCN5ASCN9A | |
| SCHEMBL20582804 | 0.77 | HRH3 (0.33) | DGAT1 | |
| SCHEMBL20183474 | 0.77 | ALOX5AP (0.43) | ACACBSCN9A | |
| SCHEMBL20183350 | 0.74 | JAK3 (0.44) | — | |
| SCHEMBL17527387 | 0.73 | PIK3CD (0.49) | — | |
| SCHEMBL18419032 | 0.73 | PIK3CD (0.49) | — | |
| SCHEMBL20893945 | 0.72 | ALDH1A1 (0.36) | KCNH2SCN5ASCN9ADGAT1 | |
| SCHEMBL22613228 | 0.72 | — | — | |
| SCHEMBL20183873 | 0.72 | GPR119 (0.51) | KCNH2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | ACACB 2379/4885KCNH2 2547/4885SCN5A 2377/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | ACACB 2748/4885KCNH2 4105/4885SCN5A 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.